Tirzepatide comparison
Mounjaro® vs Zepbound®
Same active ingredient, different FDA-approved uses. Mounjaro and Zepbound are both manufactured by Eli Lilly and contain tirzepatide, a dual GLP-1/GIP receptor agonist. However, they carry different FDA approvals. Here is what distinguishes them.
- Compared
- Mounjaro® · Zepbound®
- Sources
- FDA labels, SURPASS and SURMOUNT trial programs
Both contain tirzepatide
A dual GLP-1/GIP agonist, made by Eli Lilly.
Mounjaro®: type 2 diabetes
FDA-approved for blood sugar management.
Zepbound®: weight management
FDA-approved for chronic weight management.
Side by side
Key differences between these two tirzepatide brands.
| Feature | Mounjaro® | Zepbound® |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Drug class | Dual GLP-1/GIP receptor agonist | Dual GLP-1/GIP receptor agonist |
| FDA-approved for | Type 2 diabetes | Chronic weight management |
| Manufacturer | Eli Lilly | Eli Lilly |
| Administration | Weekly injection | Weekly injection |
| FDA approval year | 2022 | 2023 |
| Key clinical trial | SURPASS program | SURMOUNT program |
| Avg weight loss in trials | Varies by dose (secondary endpoint) | ~20.9% (SURMOUNT-1) |
| Approx list price | ~$1,023/month | ~$1,059/month |
Clinical trial results
Each brand was studied in its own clinical trial program, designed around its approved indication.
Mounjaro®: SURPASS trial program
- Primary focus: Blood sugar (A1C) reduction in type 2 diabetes patients.
- Weight loss: Observed as a secondary endpoint. Participants experienced significant weight reduction across all doses, though the trials were designed primarily for glycemic control.
- Dose range: 5mg, 10mg, and 15mg weekly injections were studied across the SURPASS trials.
- Approval basis: Superior A1C reduction compared to placebo and other diabetes medications.
Zepbound®: SURMOUNT trial program
- Primary focus: Weight loss in adults with obesity or overweight with at least one weight-related comorbidity.
- SURMOUNT-1 results: Average weight loss of approximately 20.9% of body weight at the highest dose (15mg) over 72 weeks, compared to 3.1% with placebo (2,539 participants).
- Dose-dependent: Weight loss varied by dose, with the 15mg dose showing the highest average reduction.
- Published: New England Journal of Medicine, 2022.
Why two brands for the same drug?
Common pharmaceutical practice
It is standard practice in the pharmaceutical industry for the same active ingredient to be marketed under different brand names for different approved indications. Each brand undergoes its own regulatory review process, with clinical trials designed specifically for its intended use. Novo Nordisk does the same with semaglutide (Ozempic for diabetes, Wegovy for weight loss).
Different approval pathways
Mounjaro was approved in May 2022 based on the SURPASS trials for type 2 diabetes. Zepbound was approved in November 2023 based on the SURMOUNT trials for chronic weight management. Each required separate FDA review of safety and efficacy data specific to its approved indication.
Insurance implications
Insurance coverage often depends on the approved indication. A prescription for Mounjaro may be covered under diabetes benefits, while Zepbound may fall under weight management coverage, which varies significantly between plans. This distinction matters for out-of-pocket costs.
Related comparison
Novo Nordisk follows the same pattern with semaglutide: Ozempic for diabetes and Wegovy for weight management. See our Ozempic vs Wegovy comparison for a side-by-side look at those brands.
Track any GLP-1 medication, free.
Whether you're on Mounjaro or Zepbound, Dose AI tracks your injections, symptoms, weight, and nutrition in one place.
4.7 · 994 App Store ratings · 55,000+ downloads · Featured by Apple
Questions people ask
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound contain the same active ingredient (tirzepatide) made by Eli Lilly. The key difference is their FDA-approved indication: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management. They have separate clinical trial programs and may have different insurance coverage.
Can I use Mounjaro for weight loss?
Mounjaro is not FDA-approved for weight loss. Some doctors prescribe it off-label for this purpose. Zepbound is the tirzepatide brand specifically approved for chronic weight management. Discuss with your healthcare provider which option is appropriate for your situation.
Is Zepbound the same as Mounjaro?
They contain the same active ingredient (tirzepatide) and are made by the same manufacturer (Eli Lilly), but they are different brand names with different FDA approvals. This is the same pattern as Ozempic and Wegovy, which both contain semaglutide for different indications.
Which costs more, Mounjaro or Zepbound?
Published list prices are similar (Mounjaro ~$1,023/month, Zepbound ~$1,059/month), but actual out-of-pocket costs depend on insurance coverage, pharmacy, and manufacturer savings programs. Coverage may vary based on the approved indication for which it is prescribed.
Can you switch between Mounjaro and Zepbound?
Any medication change should be discussed with your prescribing doctor. While they contain the same active ingredient, switching involves considerations about approved indications, available doses, and insurance coverage.
Does Dose AI track both Mounjaro and Zepbound?
Yes. Dose AI tracks any GLP-1 medication, including both Mounjaro and Zepbound. The app helps you log injections, track symptoms, monitor weight changes, and manage your nutrition regardless of which brand you use.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.